INS and metabolic dysfunction-associated steatotic liver disease: Addressing chronic hyperglycemia in T2D with glucose-lowering medications that are not insulin sensitizers and do not induce significant weight loss (e.g., insulin or DPP-4 inhibitors) has resulted in inconsistent results in NAFLD [49,50], downplaying the effect of chronic hyperglycemia per se on the relationship between T2D and the risk of NASH.